When should apixaban be held in a patient on chronic dialysis undergoing arteriovenous fistula creation?

When to Hold Apixaban in Dialysis Patients Undergoing AV Fistula Creation

Hold apixaban for 48 hours (2 doses) before AV fistula creation in dialysis patients, with the last dose taken on the morning of the day before surgery.

Procedural Risk Classification

AV fistula creation is classified as a low-to-moderate hemorrhagic risk procedure where surgical hemostasis can be achieved, but bleeding complications could compromise the new access 1. This classification determines the interruption strategy.

Specific Holding Protocol

Standard Interruption Timeline

For apixaban in dialysis patients:

• If twice daily dosing (2.5 mg BID): Last dose on the morning of the day before surgery (48 hours pre-procedure)
• If once daily dosing: Last dose two days before surgery if evening dosing 1

Critical Dialysis-Specific Considerations

The standard holding period must be extended beyond typical recommendations in dialysis patients because:

• Apixaban clearance is significantly reduced in ESRD, with only 27% renal excretion but substantial accumulation occurs 2
• Dialysis removes only 4% of apixaban per session, providing minimal drug clearance 3
• The half-life is approximately 12 hours in normal renal function but drug accumulation is substantial in dialysis patients 4, 3
• Recent pharmacokinetic modeling demonstrates that standard 48-72 hour discontinuation periods are insufficient to achieve clinically negligible concentrations in hemodialysis patients 4

Enhanced Safety Protocol

For optimal safety, consider 72 hours (3 days) of interruption rather than the standard 48 hours, particularly if:

• Patient is on 5 mg twice daily dosing (which leads to supratherapeutic levels in dialysis patients) 3
• Patient has additional bleeding risk factors
• Surgical team preference for minimal residual anticoagulation

Bridging Strategy

Do NOT use heparin bridging (UFH or LMWH) before AV fistula creation 1. Bridging increases bleeding risk without reducing thromboembolic events and is specifically contraindicated by current guidelines.

Timing Relative to Dialysis

• Schedule dialysis session on the day before surgery if possible, as this provides modest additional drug clearance (approximately 18 mL/min dialytic clearance) 2
• However, do not rely on dialysis for drug removal—the interruption period is the primary safety measure 3

Resumption After Surgery

Resume apixaban 24-48 hours post-operatively once surgical hemostasis is confirmed and there is no active bleeding:

• Start with prophylactic LMWH at least 6 hours post-procedure if VTE prophylaxis is needed 1
• Resume therapeutic apixaban 12 hours after the last prophylactic LMWH dose 1
• For twice daily regimen: resume the evening of post-operative day 1 or morning of post-operative day 2 1

Dosing Verification

Confirm the patient is on appropriate dosing before surgery:

• Dialysis patients should typically be on 2.5 mg twice daily, not 5 mg twice daily 3
• The 5 mg twice daily dose leads to supratherapeutic levels (trough levels 218 ng/mL, above 90th percentile for normal renal function) and should be avoided 3
• Drug levels with 2.5 mg twice daily approximate those of 5 mg twice daily in patients with preserved renal function 3, 5

Common Pitfalls to Avoid

1. Do not use standard non-CKD holding protocols—dialysis patients require longer interruption periods 4
2. Do not bridge with heparin—this increases bleeding without benefit 1
3. Do not assume dialysis will adequately clear the drug—only 4% is removed per session 3
4. Do not resume too early—wait for confirmed hemostasis (24-48 hours minimum) 1
5. Avoid neuraxial anesthesia if insufficient discontinuation time has elapsed 1

Risk-Benefit Context

While anticoagulation does not reduce AVF thrombosis rates and increases bleeding risk 6, the decision to hold apixaban is driven by the surgical bleeding risk, not by vascular access considerations. The primary indication for apixaban (typically atrial fibrillation in dialysis patients) must be balanced against the 48-72 hour interruption period, which carries acceptable short-term thromboembolic risk 1, 7.